# PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies

> **NCT05107856** · PHASE1 · TERMINATED · sponsor: **Prelude Therapeutics** · enrollment: 21 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- B-cell Non-Hodgkin Lymphoma
- Chronic Lymphocytic Leukemia
- Chronic Myelomonocytic Leukemia
- Follicular Lymphoma
- Mantle Cell Lymphoma
- Marginal Zone Lymphoma
- Myelodysplastic Syndromes
- Myeloproliferative Neoplasm
- Small Lymphocytic Lymphoma

## Interventions

- **DRUG:** PRT1419
- **DRUG:** Azacitidine
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT05107856
- **Lead sponsor:** Prelude Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-03-22
- **Primary completion:** 2024-01-19
- **Final completion:** 2024-01-19
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** Company Decision
- **Last updated:** 2024-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05107856

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05107856, "PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05107856. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*